AG真人官方

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Exemption from the $5.1 million repayment obligation strengthens 尝础痴础鈥檚 balance sheet

Underscores focus on cost curtailment and strategic option evaluation

UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- 听(狈础厂顿础蚕: LVTX, 鈥淟AVA,鈥� 鈥渢he Company鈥�), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody^庐 platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million.

鈥淎s part of 尝础痴础鈥檚 ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,鈥� said Steve Hurly, Chief Executive Officer of LAVA. 鈥淪ecuring the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.鈥�

The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee.

About LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody^庐 platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V纬9V未2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.

尝础痴础鈥檚 pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on聽,听, and聽.

Gammabody^庐 is a registered trademark of LAVA Therapeutics N.V.

尝础痴础鈥檚 Cautionary Note on Forward-Looking Statements

This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are 鈥渇orward-looking statements鈥�. Words such as 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥渃ould鈥�, 鈥渨ill鈥�, 鈥渕ay鈥�, 鈥渆xpect鈥�, 鈥渟hould鈥�, 鈥減lan鈥�, 鈥渋ntend鈥�, 鈥渆stimate鈥�, 鈥減otential鈥�, 鈥渟uggests鈥�, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on 尝础痴础鈥檚 expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to 尝础痴础鈥檚 initiatives to increase cost optimization and efficiencies. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, 尝础痴础鈥檚 ability to leverage its initial programs to develop additional product candidates using its Gammabody庐 platform, the failure of 尝础痴础鈥檚 collaborators to support or advance collaborations or 尝础痴础鈥檚 product candidates, the timing and results of 尝础痴础鈥檚 research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, 尝础痴础鈥檚 ability to obtain regulatory approval for and commercialize its product candidates, 尝础痴础鈥檚 ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on 尝础痴础鈥檚 business condition and results from general economic and market conditions and overall fluctuations in the United States and international credit and financial markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the conflict in Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption 鈥淩isk Factors鈥� in 尝础痴础鈥檚 most recent Annual Report on Form 10-K and other filings LAVA makes with the U.S. Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law.

CONTACTS
Investor Relations

LifeSci Advisors (IR/Media)
Joyce Allaire